ERBB2 and gastric cancer: The latest Chinese Society of Clinical Oncology (CSCO), the Japanese Gastric Cancer Association (JGCA), and the National Comprehensive Cancer Network (NCCN) guidelines all recommend such combination as the first-line treatment for HER2-positive metastatic gastric adenocarcinoma (Japanese Gastric Cancer Association 2021; Zhang et al. 2023; Huang et al. 2022c).